
Flaviroz 35mg Tablet MR
Marketer
Eswar Therapeutics Pvt Ltd
Salt Composition
Trimetazidine (35mg)
Overview Flaviroz 35mg Tablet MR
Cardiogard 35mg Extended-Release Tablets are prescribed for angina pectoris, a type of chest pain stemming from heart conditions. This medication acts to prevent future angina episodes but won't alleviate an attack already in progress. It's suitable for monotherapy or use alongside other cardiac medications. As directed by your physician, take Cardiogard 35mg ER tablets consistently, with or without food, at the same time each day. Dosage frequency is determined by your doctor and may adjust based on treatment effectiveness. Continuous use, even when feeling well, is vital for optimal preventative benefits. Discontinuing treatment may trigger a recurrence of chest pain. Complementary lifestyle modifications – such as smoking cessation, moderate alcohol consumption, a balanced diet, regular physical activity, and stress management – can further enhance cardiovascular health. Potential side effects, including nausea, vomiting, headache, dizziness, abdominal discomfort, diarrhea, skin rashes (itching, hives), and general weakness, may occur. Consult your doctor if these persist or are bothersome. Prior to initiating Cardiogard 35mg ER therapy, disclose any pre-existing liver or kidney conditions, pregnancy, breastfeeding, or concurrent medications to your healthcare provider, as this medication may not be appropriate for all individuals.
Uses of Flaviroz 35mg Tablet MR
Managing Chest Pain Associated with Coronary Artery Disease
Major Benefits of Flaviroz 35mg Tablet MR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet without chewing, crushing, or dividing it. The Flaviroz 35mg Modified-Release Tablet should be administered with food.
Common Side effects of Flaviroz 35mg Tablet MR:
- Dizziness
- Headache
- Nausea
- Vomiting
- Weakness
- Rash
- Abdominal pain
- Indigestion
- Itching
- Diarrhea
- Hives
How to use Flaviroz 35mg Tablet MR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Flaviroz 35mg Modified-Release Tablet should be administered with a meal.
How Flaviroz 35mg Tablet MR works:
Flaviroz 35mg Modified-Release tablets offer anti-anginal benefits. By altering cardiac metabolism, favoring glucose over fats as fuel, they reduce the heart's oxygen demand, thus improving cardiac efficiency.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of Flaviroz 35mg modified-release tablets and alcohol may result in increased sleepiness.
PregnancyCONSULT YOUR DOCTOR
Data on Flaviroz 35mg Tablet MR use in pregnancy is lacking. Seek medical advice from your physician.
Breast feedingCONSULT YOUR DOCTOR
Data on the compatibility of Flaviroz 35mg Tablet MR with breastfeeding is currently lacking. Seek medical advice from your physician.
DrivingUNSAFE
Taking Flaviroz 35mg Modified-Release Tablets might reduce attentiveness, impair vision, or cause drowsiness and dizziness. Refrain from driving if you experience these effects.
KidneyCAUTION
Patients with impaired kidney function should use Flaviroz 35mg modified-release tablets cautiously, potentially requiring dose modification. Consult a physician for guidance. Flaviroz 35mg modified-release tablets are contraindicated in individuals with severe kidney disease.
LiverCONSULT YOUR DOCTOR
Data regarding the use of Flaviroz 35mg MR tablets in individuals with hepatic impairment is scarce. Physician consultation is advised.
What if you forget to take Flaviroz 35mg Tablet MR :
Should you forget to take a Flaviroz 35mg Tablet MR, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Flaviroz 35mg Tablet MR
| Label | Value |
|---|---|
| Chemical Classification | Benzylamines |
| Developing Habits | No. |
| Treatment Category | Heart |
| Action Class | Fatty acid modulator and sodium channel inhibitor |
